CHAPEL HILL, N.C., Nov. 5 /PRNewswire/ -- As biopharmaceutical companies continue to bring new therapies to market, considerable efforts are placed on strategy and execution from development through launch, while post-launch evaluations largely focus on revenue growth and little else. In a continuing effort to support product launch excellence, a recent study was conducted by Best Practices, LLC reviewing launch evaluation with insights available in the newly published report, "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success." This research initiative explored excellence in launch evaluation yielding key findings into continuous improvement strategies, plans and practices for both current and future landscapes across the biopharmaceutical industry.
To view the study abstract or complimentary summary of the full report "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success," click on the following link http://www3.best-in-class.com/rr974.htm.
In a benchmarking study that included such influential companies as
Abbott, GlaxoSmithKline, Novo Nordisk, Roche, and Sanofi-Aventis, many key
topics were covered, including:
-- Understand Product Launch Evaluation Process
-- Determine Role of Forecasting in Evaluating Success
-- Identify Key Performance Measures Used
-- Review Importance of Specific Launch Evaluation Performance Measures
-- Describe Process and Timetable for Recalibration of Launch Targets
For more information on this report, contact Robert Naylor at firstname.lastname@example.org or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr974.htm.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.
|SOURCE Best Practices, LLC|
Copyright©2008 PR Newswire.
All rights reserved